You are currently viewing Mirror Biologics Finishes AlloPrime Vaccine Phase I/II clinical Trial For Protecting Elderly from Community-Acquired Pneumonia

Mirror Biologics is developing an innovative universal anti-respiratory viral vaccine, AlloPrime, for the protection of the elderly from serious community-acquired viral infections. A phase I/II clinical trial of AlloPrime in 40 subjects over 65 years has completed accrual and awaiting data maturity and analysis. The AlloPrime remodels the senescent immune systems of the elderly so that they can respond effectively to viral infections in the same manner as healthy youthful immune systems. The AlloPrime protocols are reverse-engineered from the study of the immune mechanisms of the young and healthy. This could become extremely good news for future viral outbreaks of flu and coronavirus, as the mechanism does not require any prior knowledge of the type of virus or the genetic composition of the virus.

Community-acquired pneumonia (CAP) is a frequent and deadly infection affecting the elderly, having considerable implications for healthcare systems worldwide. CAP is responsible globally for 3 million deaths annually!

Viral causes of Community-acquired pneumonia (CAP)

The most common viral causes are influenza, parainfluenza, human respiratory syncytial virus, human metapneumovirus, and adenovirus. More recently the coronavirus left its mark on the world especially targeting the elderly. Less common viruses which may cause serious illness include chickenpox, SARS, avian flu, and hantavirus.

Typically, a virus enters the lungs through the inhalation of water droplets and invades the cells lining the airways and the alveoli. This leads to cell death; the cells are killed by the virus or they self-destruct. Further lung damage occurs when the immune system responds to the infection. White blood cells, particularly lymphocytes, activate chemicals known as cytokines which cause fluid to leak into the alveoli. The combination of cell destruction and fluid-filled alveoli interrupts the transportation of oxygen into the bloodstream. In addition to their effects on the lungs, many viruses affect other organs. Viral infections weaken the immune system, making the body more susceptible to bacterial infections, including bacterial pneumonia.

AlloPrime Defense Mechanism

The world’s population is aging rapidly. By 2050, the number of people over the age of 60 is projected to double to 2.1 billion. This aging population is a global challenge, but it also presents an opportunity for innovation.

Cellular immune function weakens as we age, making the elderly susceptible to CAP viral disease, while healthy young people with strong cellular immunity rarely suffer serious illness from the same viral infection.

The Mirror vaccine known as “AlloPrime” is designed to restore cellular immune function in the elderly so that the immune system responds to viral infection in the same manner as a young immune system would respond. A key component of this mechanism is priming the elderly to have strong cellular immune function prior to encountering a virus. When the cellular system is weak, a delayed immune response occurs that allows viral titers to become high and then a late response “over-reacts” to the virus causing considerable damage to the respiratory system. A strong cellular immune response eliminates the virus early before any damage occurs.

It is also important to find ways to protect the elderly as a countermeasure to the next possible viral pandemic. AlloPrime is unique as a vaccine, as it can provide protection from both known and unknown viruses without the requirement of any knowledge of the antigenic structure of the virus.

Mirror Biologics has three separate drugs under development using their proprietary allogeneic (using stem cells from healthy donors) stem cell-based immunotherapy:

  1. AlloStim (anti-cancer vaccine),
  2. AlloPrime (Vaccine for protecting the elderly from community-acquired pneumonia),
  3. AlloLife (Vaccine for middle age individuals suffering from chronic inflammation)

These three separate drugs are based on patented, bioengineered cell therapy that is not genetically manipulated and is “off-the-shelf”.

“As more information is learned about the immune mechanisms that fail to protect against disease and mechanisms that are successful, it provides an opportunity to use our Mirror Effect technology to reverse engineer successful immune responses and imprint these responses to dominate over resident failed responses. This approach to immunotherapy has the potential to benefit patients by preventing and treating some of the most difficult diseases in a manner that is both natural and able to maintain quality of life. The Mirror Biologics worldwide team is excited to be at the forefront of this new approach to immunotherapy and we are committed to making these therapies available to those that might benefit” stated Dr Michael Har-Noy, Founder and CEO of Mirror Biologics.

About Mirror Biologics Inc.

Mirror Biologics, Inc. is a private Delaware corporation incorporated on November 5th, 2018 with headquarters in Tampa, Florida, and with operations in Jerusalem, Israel, Bangkok, Thailand, and Kuala Lumpur, Malaysia. In Tampa, Florida where it conducts advanced bioreactor research and prototype development for commercial manufacturing and operates an FDA-registered 21 CFR 1271-compliant blood donor and cell processing center and a Phase I/II clinical research center. In Jerusalem, Mirror Biologics operates a GMP cell manufacturing and research facility and is expected to move into its new facilities in Har Hotzvim later this year. Dr. Elena Fingerut is the General Manager ofMirror Biologics, Ltd., its wholly-owned Israel subsidiary. Mirror Biologics also has offices in Bangkok, Thailand, and Kuala Lumpur, Malaysia which provide clinical trial management and local drug depo and distribution.

Their lead AlloStim® product candidate is an “off-the-shelf,” non-genetically manipulated, disease agnostic, patented, living immune cell derived from healthy blood donors. Mirror Biologics, Inc. specializes in the discovery, clinical testing, and manufacturing of next-generation therapeutic and prophylactic immunotherapy vaccine products which incorporate living immune cells as active ingredients. Mirror Biologics, Inc. is driven by compassion for patients suffering from incurable diseases and highly toxic therapies to provide non-toxic, affordable alternative immunotherapy treatment options with a curative or life-extending activity that can be made widely accessible and capable of distribution to out-patient clinics in both urban and rural areas worldwide.

For further information on Mirror Biologics, Inc.
Contact:  info AT mirrorbio.com      Website: Mirror Biologics   https://www.mirrorbio.com/

About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/

JLM-BioCity  is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.

We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your Company featured in our blogs, or news releases, please contact: info at jlm-biocity.org